Avandia Decision a Moot Point for Prescribers?

(MedPage Today) -- It's unlikely that the FDA's decision to loosen some of the restrictions on the type 2 diabetes drug rosiglitazone (Avandia) will have any impact on prescribing in the U.S., according to several experts contacted by MedPage Today.
Source: MedPage Today Public Health - Category: American Health Source Type: news